---
layout: default
title: Donepezil Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 182
evidence_level: L5
indication_count: 0
---

# Donepezil Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Donepezil Hydrochloride: Evidence Pack Incomplete — Awaiting TxGNN Predictions

---

## One-Sentence Summary

Donepezil hydrochloride is a reversible acetylcholinesterase inhibitor internationally established for Alzheimer's disease and related dementias.
This Evidence Pack was generated with critical data gaps — the TxGNN pipeline has **not returned any predicted new indications**, and SAHPRA regulatory and safety records are absent.
**No repurposing recommendation can be issued at this time; the decision is Hold pending data resolution.**

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | None returned by TxGNN |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — Model prediction not yet completed |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Background on This Drug

Currently, detailed mechanism of action data is not available in this Evidence Pack (Data Gap DG002). Based on published pharmacological knowledge, donepezil hydrochloride is a **reversible, selective acetylcholinesterase (AChE) inhibitor**. By preventing the enzymatic breakdown of acetylcholine at cholinergic synapses in the central nervous system, it sustains and amplifies cholinergic neurotransmission in regions critical to memory and cognition — most notably the hippocampus and cerebral cortex.

Donepezil is internationally registered and widely used for **mild, moderate, and severe Alzheimer's disease**, as well as for dementia associated with Parkinson's disease. It does not carry an antineoplastic mechanism.

Once TxGNN predictions are available, any predicted new indication should be evaluated against this cholinergic mechanism. Candidate areas likely to show mechanistic plausibility include other neurodegenerative conditions, neuropsychiatric disorders, or conditions involving impaired cholinergic signalling.

> **Note:** The DrugBank query for this drug returned 1 result (query date 2026-03-26, status: success). That data has not been incorporated into this Evidence Pack. Retrieving DrugBank MOA, categories, and safety data should be the first remediation step.

---

## South Africa Market Information

Donepezil hydrochloride is currently **not registered with SAHPRA** and holds no marketing authorisation in South Africa. No registration records are available.

> Donepezil is registered and in active clinical use in many other jurisdictions, including the United States (FDA), European Union (EMA), and United Kingdom (MHRA), for Alzheimer's disease. The absence of SAHPRA registration reflects the local regulatory status only.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

> Key warnings and contraindications data were flagged as a **Blocking data gap (DG001)** in this Evidence Pack. No safety evaluation can proceed until the PI or equivalent source is obtained and reviewed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is materially incomplete — there are no TxGNN-predicted indications, no SAHPRA registration data, and no verified safety information. A repurposing recommendation cannot responsibly be made in the absence of these foundational inputs.

**To proceed, the following is needed:**

1. **Run TxGNN prediction pipeline** for Donepezil Hydrochloride to generate predicted new indications and evidence links
2. **Incorporate the DrugBank record** already retrieved (1 result confirmed) — extract MOA, drug categories, toxicity, and DDI data (resolves DG002)
3. **Obtain SAHPRA PI or international equivalent** (e.g., FDA label, EMA SmPC) for key warnings, contraindications, and monitoring requirements (resolves DG001 — currently Blocking)
4. **Clarify original approved indications** — populate `original_indications` field from the DrugBank or PI source
5. **Assess SAHPRA registration pathway** — if a repurposing candidate is identified and evidence is sufficient, determine whether a new application or Section 21 authorisation is required given current zero-registration status in South Africa
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

